[go: up one dir, main page]

BR9407507A - Co-transfection plasmid protein for co-transfection with viral DNA live recombinant vehicle against coronavirus vaccine and processes for preparing a DNA molecule and a coronavirus and FIPV cacin to protect a mammal from coronavirus infection and a FIPV feline - Google Patents

Co-transfection plasmid protein for co-transfection with viral DNA live recombinant vehicle against coronavirus vaccine and processes for preparing a DNA molecule and a coronavirus and FIPV cacin to protect a mammal from coronavirus infection and a FIPV feline

Info

Publication number
BR9407507A
BR9407507A BR9407507A BR9407507A BR9407507A BR 9407507 A BR9407507 A BR 9407507A BR 9407507 A BR9407507 A BR 9407507A BR 9407507 A BR9407507 A BR 9407507A BR 9407507 A BR9407507 A BR 9407507A
Authority
BR
Brazil
Prior art keywords
coronavirus
fipv
transfection
cacin
feline
Prior art date
Application number
BR9407507A
Other languages
Portuguese (pt)
Inventor
Michel Bublot
Catherine De Wannemaeker
Didier Colau
Philippe Roux Salembien
Original Assignee
Solvay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay filed Critical Solvay
Publication of BR9407507A publication Critical patent/BR9407507A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR9407507A 1993-09-16 1994-09-07 Co-transfection plasmid protein for co-transfection with viral DNA live recombinant vehicle against coronavirus vaccine and processes for preparing a DNA molecule and a coronavirus and FIPV cacin to protect a mammal from coronavirus infection and a FIPV feline BR9407507A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9319212A GB2282601B (en) 1993-09-16 1993-09-16 Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same
PCT/EP1994/002990 WO1995007987A2 (en) 1993-09-16 1994-09-07 Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor

Publications (1)

Publication Number Publication Date
BR9407507A true BR9407507A (en) 1997-01-07

Family

ID=10742112

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9407507A BR9407507A (en) 1993-09-16 1994-09-07 Co-transfection plasmid protein for co-transfection with viral DNA live recombinant vehicle against coronavirus vaccine and processes for preparing a DNA molecule and a coronavirus and FIPV cacin to protect a mammal from coronavirus infection and a FIPV feline

Country Status (10)

Country Link
EP (1) EP0720654A1 (en)
JP (1) JPH09509562A (en)
KR (1) KR960705047A (en)
AU (1) AU7615894A (en)
BR (1) BR9407507A (en)
CA (1) CA2171869A1 (en)
GB (2) GB2282601B (en)
NO (1) NO961086L (en)
WO (1) WO1995007987A2 (en)
ZA (1) ZA946887B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724385B1 (en) * 1994-08-29 1996-12-13 Rhone Merieux FELINE INFECTIOUS PERITONITIS VACCINE.
FR2741806B1 (en) * 1995-11-30 1998-02-20 Rhone Merieux RECOMBINANT LIVING VACCINE BASED ON TYPE 1 FELINE HERPESVIRUS, PARTICULARLY AGAINST FELIN INFECTIOUS PERITONITIS
WO1998001570A2 (en) * 1996-07-05 1998-01-15 Vanderbilt University Mutated antibody-dependent infection enhancing domains of hiv
FR2751223B1 (en) * 1996-07-19 1998-12-04 Rhone Merieux FELIN POLYNUCLEOTIDE VACCINE FORMULA
CN1223605C (en) * 2003-05-16 2005-10-19 中国科学院微生物研究所 Polypeptide medicine for inhibiting SARS coronavirus, and derivatives and use thereof
CN113321714B (en) * 2020-02-28 2022-12-09 深圳市亚辉龙生物科技股份有限公司 Recombinant N protein of SARS-CoV-2 and its preparation and purification method
US20230331782A1 (en) * 2020-09-08 2023-10-19 The Trustees Of The University Of Pennsylvania Compositions and Methods for Reducing Risk of Vaccine-Enhanced Disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU576907B2 (en) * 1984-11-01 1988-09-08 American Home Products Corporation Oral vaccines comprising live recombinant adenoviruses
EP0264979A1 (en) * 1986-09-05 1988-04-27 Duphar International Research B.V New antigenically active proteins and peptides, and feline infectious peritonitis virus (FIPV) vaccines
CA2005291C (en) * 1988-12-30 1999-01-26 Beverly Dale Feline infectious peritonitis virus diagnostic tools
CA2020740A1 (en) * 1989-07-12 1991-01-13 Harry Vennema Antigenically active proteins/peptides, and feline infectious peritonitis virus (fipv)-vaccines
NZ240558A (en) * 1990-11-14 1994-11-25 Smithkline Beecham Corp Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease
WO1993015762A1 (en) * 1992-02-18 1993-08-19 Parhelion Corporation Feline infectious peritonitis vaccine and method of preparation
CA2135200C (en) * 1992-05-08 2001-03-27 Timothy J. Miller Canine coronavirus s gene and uses therefor
AU678971B2 (en) * 1992-05-08 1997-06-19 Pfizer Inc. Compositions and methods for vaccination against coronaviruses

Also Published As

Publication number Publication date
GB2316681A (en) 1998-03-04
WO1995007987A3 (en) 1995-06-22
GB2316681B (en) 1998-04-15
GB2282601A (en) 1995-04-12
ZA946887B (en) 1995-06-27
CA2171869A1 (en) 1995-03-23
GB9319212D0 (en) 1993-11-03
GB9722558D0 (en) 1997-12-24
KR960705047A (en) 1996-10-09
NO961086L (en) 1996-05-09
GB2282601B (en) 1998-04-15
NO961086D0 (en) 1996-03-15
EP0720654A1 (en) 1996-07-10
AU7615894A (en) 1995-04-03
WO1995007987A2 (en) 1995-03-23
JPH09509562A (en) 1997-09-30

Similar Documents

Publication Publication Date Title
PT90731A (en) PROCESS FOR THE PREPARATION OF A RECOMBINANT, VACCINE DNA MOLECULE FOR PROTECTION AGAINST HIV AND DIAGNOSIS OF HIV EXPOSURE
GB2246784B (en) Herpes virus recombinant poxvirus vaccine
EP1009434A4 (en) Stabilizers containing recombinant human serum albumin for live virus vaccines
RU95115239A (en) Erythropoietin analog
BR1100637A (en) "recombinant turkey herpes virus (hvt), recombinant hvt, nucleic acid sequence, molecupara the preparation of a recombinant hvt, culture a vaccine, process for the preparation of a vaccine, pharmaceutical or diagnostic composition and antiserum"
DK0797678T3 (en) Hybrid adenovirus AAV virus and methods for using it
AR003425A1 (en) RECOMBINANT MAPACHE POXVIRUS, VACCINE FOR USE IN CATS AND USE OF POXVIRUS TO PREPARE A VACCINE USEFUL TO AVOID OR DECREASE THE DISEASE CAUSED BY THE FELINE IMMUNODEFICIENCY VIRUS (IVF)
ATE420190T1 (en) RECOMBINANT LIVE VACCINE CONTAINING FELINE HERPES VIRUS TYPE I, ESPECIALLY FOR THE TREATMENT OF INFECTIOUS PERIMONITIS IN CATS
EP1000174A4 (en) PURIFICATION TECHNIQUE FOR VIRAL NUCLEIC ACIDS
FR2620459B1 (en) RECOMBINANT VACCINE VIRUS
BR9407507A (en) Co-transfection plasmid protein for co-transfection with viral DNA live recombinant vehicle against coronavirus vaccine and processes for preparing a DNA molecule and a coronavirus and FIPV cacin to protect a mammal from coronavirus infection and a FIPV feline
FI973309L (en) Method for preparing a recombinant DNA adenovirus genome
CA2364499A1 (en) Means and methods for fibroblast-like or macrophage-like cell transduction
SG55095A1 (en) Viruses and their use as a vaccine against feline infectious peritonitis virus disease
DE69934583D1 (en) NUCLEIC ACID VACCINES FOR PREVENTING FLAVIVIREN INFECTION
EP1100545A4 (en) Regulated expression of recombinant proteins using rna viruses
WO1997003187A3 (en) Marek's disease virus genes and their use in vaccines for protection against marek's disease
CA2198743A1 (en) Feline infectious peritonitis vaccine
FR2756491B1 (en) TRANSFECTING COMPOSITION USEFUL IN GENE THERAPY ASSOCIATED WITH A RECOMBINANT VIRUS INCORPORATING EXOG ENE NUCLEIC ACID, A NON-VIRAL AND NON-PLASMIDIC TRANSFECTING AGENT
GB8919102D0 (en) A recombinant adenovirus dna sequence,a recombinant adenovirus expressing the dna sequence and a rhabdovirus vaccine including the recombinant adenovirus
BR9801992A (en) Processes for the preparation of viruses of marek disease using continuous mammalian cell lines.
DE69738969D1 (en) PROCESS FOR EXPRESSING AND PREPARING THE RECOMBINANT PROTEIN GP90 OF THE GLYCOPROTEIN SHELL IN THE INFECTIOUS HORSE ANEMIA VIRUS EIAV
NZ331889A (en) Trypanosomatids histones for use as an antigen against trypanosomatic infection, including diagnostic tests, pharmaceutical compositions and vaccines of these antigens
AU7276198A (en) Live virus vaccines to protect primates from hiv-1 infection and disease
AU6268199A (en) Live virus vaccines to protect primates from hiv-1 infection and disease

Legal Events

Date Code Title Description
PC Transfer

Free format text: DIMMINACO AG/SA/LTD (CH)

EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal